When does Gammagard’s patent end?
No specific “Gammagard patent” end date is provided in the information available here. Gammagard is an immunoglobulin product, and the timing of when competing products can launch depends on which exact patent (and which geography) is being referenced, along with related patent terms and any exclusivity or litigation status.
Which patents control Gammagard’s end date?
For biologic/infusion products like Gammagard, there can be multiple controlling rights rather than one single patent. The “end date” people quote usually comes from a particular set of patents (for example, formulation, manufacturing process, or specific indications) and can differ by:
- Country (US vs. EU vs. other markets)
- The specific Gammagard product/version (e.g., liquid vs. lyophilized, different presentations)
- The patent family and whether any patents are still in force or have been challenged
What you can check to get the exact end date
To determine the true “patent end” date, you’d typically look up:
- The patent numbers listed for the product in that jurisdiction
- The latest expiration dates for each relevant patent in the family
- Any extensions, pediatric exclusivity, or other term adjustments (where applicable)
- Ongoing litigation or stays that can affect launch timing even after expiration
If you tell me which country’s patent you mean (for example, US) and which exact Gammagard product name (presentation/form), I can narrow down what to look for and how to translate that into an expiration/launch window.
Is it possible for competitors to launch before every patent expires?
Yes. Even if some patents remain, a competitor may be able to launch if they avoid the specific protected claims (or if a relevant patent is invalidated/expired). Launch timing is often driven by the last-to-expire controlling patent(s) and any regulatory exclusivity rules that apply in that market.
Sources
No sources were provided with the question, so I can’t cite a specific expiration date.